Overview
- Cold Spring Harbor Laboratory researchers report that blocking or deleting PTP1B improved learning and memory and lowered amyloid‑β levels in an Alzheimer’s mouse model.
- The study maps a PTP1B–SYK interaction that restores microglial clearance of plaques and links the effect to metabolic signaling through the AKT‑mTOR pathway.
- Mice aged 12–13 months received the inhibitor DPM‑1003 at 5 mg/kg twice weekly for five weeks before behavioral testing and plaque assessment, with sample sizes not disclosed.
- The Tonks lab is collaborating with DepYmed to develop PTP1B inhibitors and envisions pairing them with approved amyloid‑targeting drugs, though development remains at the preclinical stage.
- PTP1B is a validated target in obesity and type 2 diabetes, and the modest benefits of current amyloid‑focused therapies underscore the rationale for pursuing this approach.